Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Applied Molecular Transport Inc is a biotechnology business based in the US. Applied Molecular Transport shares (AMTI) are listed on the NASDAQ and all prices are listed in US Dollars. Applied Molecular Transport employs 64 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.
|Latest market close||USD$30.59|
|52-week range||USD$17.045 - USD$36.21|
|50-day moving average||USD$31.2873|
|200-day moving average||USD$27.8077|
|Wall St. target price||USD$34.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.2214|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-9.42%|
|1 month (2020-12-17)||-8.25%|
|3 months (2020-10-15)||-5.70%|
|6 months (2020-07-15)||49.07%|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$-14,228,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 1.5 million Applied Molecular Transport shares held short by investors – that's known as Applied Molecular Transport's "short interest". This figure is 10.5% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Applied Molecular Transport shares can be evaluated.
Applied Molecular Transport's "short interest ratio" (SIR) is the quantity of Applied Molecular Transport shares currently shorted divided by the average quantity of Applied Molecular Transport shares traded daily (recently around 125493.94435352). Applied Molecular Transport's SIR currently stands at 12.22. In other words for every 100,000 Applied Molecular Transport shares traded daily on the market, roughly 12220 shares are currently held short.
However Applied Molecular Transport's short interest can also be evaluated against the total number of Applied Molecular Transport shares, or, against the total number of tradable Applied Molecular Transport shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Applied Molecular Transport's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Applied Molecular Transport shares in existence, roughly 50 shares are currently held short) or 0.1059% of the tradable shares (for every 100,000 tradable Applied Molecular Transport shares, roughly 106 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Applied Molecular Transport.
Find out more about how you can short Applied Molecular Transport stock.
We're not expecting Applied Molecular Transport to pay a dividend over the next 12 months.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its lead product candidate is AMT-101, an oral gastrointestinal (GI) selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The company, through its technology platform designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and RNA therapeutics. In addition, it engages in the development of AMT-126, a GI-selective oral fusion of rhIL-22 for diseases related to intestinal epithelium barrier function defects. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.